Evonik has launched a non-animal-derived squalene suitable for vaccines and other pharmaceutical applications. PhytoSquene® is the first known amaranth oil-derived squalene on the market for use in adjuvants in parenteral dosage forms. It meets the demand for a secure commercial supply of non-animal-derived squalene. Non-GMP samples of PhytoSquene® are available immediately with GMP quality to follow in 2023.
Evonik, one of the world’s leading silica producers, entered a strategic cooperation with the Pörner Group, Austria, and Phichit Bio Power Co., Ltd., Thailand, to supply sustainable ULTRASIL® precipitated silica to tire manufacturers. The key raw material for the sustainable silica is sodium silicate, which is derived from rice husk ash (RHA), an agricultural waste product, and produced exclusively with green energy.
Evonik Venture Capital has invested in two sustainability funds: Azolla Ventures I and the Chrysalix Venture Capital’s Carbon Neutrality Fund. Both companies are looking into CO2 reduction technologies, with Azolla focused on North America and Chrysalix globally. This is Evonik’s venture capital arm’s first investment using the new €150 million Sustainability Tech Fund. All parties have agreed to not disclose the amount of the investment.
Evonik has made a follow-up investment in the biotechnology start-up In Ovo through its venture capital unit. The investment comes as the young company reaches the commercialization stage for its technology and is bringing its gender-testing machine for eggs to the market. Together with co-investor VisVires New Protein Capital, Evonik Venture Capital has provided several million euros in further funding. Evonik Venture Capital first invested in the Leiden, Netherlands-based company in 2018, providing support for a technology that helps solve one of the egg industry’s biggest ethical problems.
Green hydrogen is a beacon of hope in the energy transition, both as a carbon-free fuel for industry and transportation, and as a key raw material for the chemical industry. Green hydrogen is produced from water by electrolysis using electricity generated from renewable resources. It is still much more expensive than conventional hydrogen, which is generally obtained from methane gas in a process that releases carbon dioxide. As well as sufficient low-cost electricity generated from renewables, investment in the electrolyzer is a key factor in cost-efficient production of green hydrogen.
Beiersdorf and Evonik have reached an agreement on a research partnership. Its aim is to develop sustainable raw materials for care products, using carbon dioxide (CO2) as the starting material. Beiersdorf is on the lookout for new sources of raw materials that will also reduce the company’s carbon footprint. One option here is artificial photosynthesis technology. The idea: with the aid of electricity from solar energy and bacteria, valuable raw materials are produced with water and CO2, drawing on natural photosynthesis as a model. The joint research project of Evonik and Beiersdorf is being funded by Germany’s Federal Ministry of Education and Research (BMBF) in the amount of around €1 million.
Evonik Venture Capital is investing in a start-up, Modern Meadow, which sustainably produces biofabricated materials that closely resemble leather, eliminating the need for animal skins. Modern Meadow has developed a technology to produce animal-free collagen, a protein naturally found in animal hides. The process involves fermentation using yeast cells.
Evonik, one of the world leaders in specialty chemicals, signed a purchase agreement for acquisition of the probiotics business of the Spanish company Norel, a global supplier of animal feed ingredients.
The agreement sees Evonik acquiring Norel’s probiotics product portfolio as well as the company’s site in León (Spain). The business will be integrated into Evonik’s Animal Nutrition Business Line. The parties have agreed not to disclose details of the transaction.
Evonik expands its green venture capital activities into Asia. The German company announced last Thursday an investment in the Chinese venture capital fund GRC SinoGreen Fund III (GRC III). The parties agreed to not disclose the amount of the investment. As a result, the company is now represented in the most important venture capital regions of North America, Europe, and Asia. GRC invests in private, green technology companies with unique strengths and substantial growth potential in Greater China. Target sectors include energy and resource efficiency, cleaner transportation, sustainability, and climate change mitigation and adaptation.
Using creativity and unconventional ideas, researchers and engineers at Evonik, one of the world leaders in specialty chemicals, have achieved a significant breakthrough in the biotechnological production of amino acids based on fermentation. They integrated the separating methods of chromatography and reverse osmosis and an online analytical method based on spectroscopy—all of which tend to be used in other industry sectors—in a biotechnological process. This created an outcome experts had previously considered nearly impossible. The researchers’ objective was to achieve optimal separation of the desired amino acid from a fermentation broth.